85 related articles for article (PubMed ID: 38691233)
21. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
Cercek A; Lumish M; Sinopoli J; Weiss J; Shia J; Lamendola-Essel M; El Dika IH; Segal N; Shcherba M; Sugarman R; Stadler Z; Yaeger R; Smith JJ; Rousseau B; Argiles G; Patel M; Desai A; Saltz LB; Widmar M; Iyer K; Zhang J; Gianino N; Crane C; Romesser PB; Pappou EP; Paty P; Garcia-Aguilar J; Gonen M; Gollub M; Weiser MR; Schalper KA; Diaz LA
N Engl J Med; 2022 Jun; 386(25):2363-2376. PubMed ID: 35660797
[TBL] [Abstract][Full Text] [Related]
22.
Ciombor KK; Strickler JH; Bekaii-Saab TS; Yaeger R
J Clin Oncol; 2022 Aug; 40(24):2706-2715. PubMed ID: 35649231
[No Abstract] [Full Text] [Related]
23. Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review.
Mori R; Uemura M; Sekido Y; Hata T; Ogino T; Takahashi H; Miyoshi N; Mizushima T; Doki Y; Eguchi H
World J Surg Oncol; 2022 May; 20(1):166. PubMed ID: 35619103
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going.
Sun C; España S; Buges C; Layos L; Hierro C; Manzano JL
Clin Colorectal Cancer; 2022 Jun; 21(2):71-79. PubMed ID: 35277355
[TBL] [Abstract][Full Text] [Related]
25. Pathological Complete Response of Clinical T4b Ascending Colon Cancer after Preoperative Chemotherapy Using Pembrolizumab.
Yoshida T; Miki H; Satake H; Kobayashi T; Matsumi Y; Hamada M; Boku S; Shibata N; Ishida M; Sekimoto M
Case Rep Oncol; 2021; 14(3):1497-1504. PubMed ID: 34899242
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial.
Nakamura Y; Okamoto W; Kato T; Esaki T; Kato K; Komatsu Y; Yuki S; Masuishi T; Nishina T; Ebi H; Sawada K; Taniguchi H; Fuse N; Nomura S; Fukui M; Matsuda S; Sakamoto Y; Uchigata H; Kitajima K; Kuramoto N; Asakawa T; Olsen S; Odegaard JI; Sato A; Fujii S; Ohtsu A; Yoshino T
Nat Med; 2021 Nov; 27(11):1899-1903. PubMed ID: 34764486
[TBL] [Abstract][Full Text] [Related]
27. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
28. Response to Pembrolizumab in Advanced Anal Squamous Cell Carcinoma With High TMB and PD-L1 and PD-L2 Amplification.
Tostes FT; Fernandes I; Segatelli V; Callegaro D; Carmagnani Pestana R
Clin Colorectal Cancer; 2021 Dec; 20(4):350-353. PubMed ID: 34154923
[TBL] [Abstract][Full Text] [Related]
29. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study.
Fernandez LM; São Julião GP; Figueiredo NL; Beets GL; van der Valk MJM; Bahadoer RR; Hilling DE; Meershoek-Klein Kranenbarg E; Roodvoets AGH; Renehan AG; van de Velde CJH; Habr-Gama A; Perez RO;
Lancet Oncol; 2021 Jan; 22(1):43-50. PubMed ID: 33316218
[TBL] [Abstract][Full Text] [Related]
30. Pathologic Complete Response in Patient With ATM Mutation After Neoadjuvant FOLFOXIRI Plus Panitumumab Therapy for Locally Advanced Colon Cancer: A Case Report.
McGillivray E; Farma J; Savage M; Hall MJ; Luo B; Jain R
Clin Colorectal Cancer; 2021 Jun; 20(2):e96-e99. PubMed ID: 33121919
[No Abstract] [Full Text] [Related]
31. Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age.
Pereira AAL; Fernandes GDS; Braga GTP; Marchetti KR; Mascarenhas CDC; Gumz B; Crosara M; Dib L; Girardi D; Barrichello A; Seidler H
Clin Colorectal Cancer; 2020 Dec; 19(4):e264-e271. PubMed ID: 32741580
[TBL] [Abstract][Full Text] [Related]
32. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Argilés G; Tabernero J; Labianca R; Hochhauser D; Salazar R; Iveson T; Laurent-Puig P; Quirke P; Yoshino T; Taieb J; Martinelli E; Arnold D;
Ann Oncol; 2020 Oct; 31(10):1291-1305. PubMed ID: 32702383
[No Abstract] [Full Text] [Related]
33. Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series.
Demisse R; Damle N; Kim E; Gong J; Fakih M; Eng C; Oesterich L; McKenny M; Ji J; Liu J; Louie R; Tam K; Gholami S; Halabi W; Monjazeb A; Dayyani F; Cho M
J Natl Compr Canc Netw; 2020 Jul; 18(7):798-804. PubMed ID: 32634770
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Chalabi M; Fanchi LF; Dijkstra KK; Van den Berg JG; Aalbers AG; Sikorska K; Lopez-Yurda M; Grootscholten C; Beets GL; Snaebjornsson P; Maas M; Mertz M; Veninga V; Bounova G; Broeks A; Beets-Tan RG; de Wijkerslooth TR; van Lent AU; Marsman HA; Nuijten E; Kok NF; Kuiper M; Verbeek WH; Kok M; Van Leerdam ME; Schumacher TN; Voest EE; Haanen JB
Nat Med; 2020 Apr; 26(4):566-576. PubMed ID: 32251400
[TBL] [Abstract][Full Text] [Related]
35. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
Thomas J; Leal A; Overman MJ
Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
[TBL] [Abstract][Full Text] [Related]
36. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.
Hashiguchi Y; Muro K; Saito Y; Ito Y; Ajioka Y; Hamaguchi T; Hasegawa K; Hotta K; Ishida H; Ishiguro M; Ishihara S; Kanemitsu Y; Kinugasa Y; Murofushi K; Nakajima TE; Oka S; Tanaka T; Taniguchi H; Tsuji A; Uehara K; Ueno H; Yamanaka T; Yamazaki K; Yoshida M; Yoshino T; Itabashi M; Sakamaki K; Sano K; Shimada Y; Tanaka S; Uetake H; Yamaguchi S; Yamaguchi N; Kobayashi H; Matsuda K; Kotake K; Sugihara K;
Int J Clin Oncol; 2020 Jan; 25(1):1-42. PubMed ID: 31203527
[TBL] [Abstract][Full Text] [Related]
37. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy.
Smith JJ; Strombom P; Chow OS; Roxburgh CS; Lynn P; Eaton A; Widmar M; Ganesh K; Yaeger R; Cercek A; Weiser MR; Nash GM; Guillem JG; Temple LKF; Chalasani SB; Fuqua JL; Petkovska I; Wu AJ; Reyngold M; Vakiani E; Shia J; Segal NH; Smith JD; Crane C; Gollub MJ; Gonen M; Saltz LB; Garcia-Aguilar J; Paty PB
JAMA Oncol; 2019 Apr; 5(4):e185896. PubMed ID: 30629084
[TBL] [Abstract][Full Text] [Related]
38. Microsatellite Instability (MSI) as an Independent Predictor of Pathologic Complete Response (PCR) in Locally Advanced Rectal Cancer: A National Cancer Database (NCDB) Analysis.
Hasan S; Renz P; Wegner RE; Finley G; Raj M; Monga D; McCormick J; Kirichenko A
Ann Surg; 2020 Apr; 271(4):716-723. PubMed ID: 30216221
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.
van der Valk MJM; Hilling DE; Bastiaannet E; Meershoek-Klein Kranenbarg E; Beets GL; Figueiredo NL; Habr-Gama A; Perez RO; Renehan AG; van de Velde CJH;
Lancet; 2018 Jun; 391(10139):2537-2545. PubMed ID: 29976470
[TBL] [Abstract][Full Text] [Related]
40. Two Months of Therapy: A Case of Pathologic Complete Response to Chemoimmunotherapy in a Patient With Metastatic Colorectal Cancer.
Armstrong S; Al-Ghawi H; Helft P; House MG; Spittler AJ; Wu HH; Shahda S
Clin Colorectal Cancer; 2018 Jun; 17(2):e229-e232. PubMed ID: 29311032
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
